ImmunityBio (IBRX) Change in Acquisitions & Divestments (2015 - 2026)

ImmunityBio (IBRX) has reported Change in Acquisitions & Divestments for 12 consecutive years, with $39.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments rose 644.82% year-over-year to $39.8 million; the TTM figure through Mar 2026 stood at $99.4 million (up 291.47% YoY), while the FY2025 annual figure was $64.9 million, up 208.72% from the prior year.
• Change in Acquisitions & Divestments slipped to $39.8 million in Q1 2026 per IBRX's latest filing, from $59.5 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $59.5 million in Q4 2025 and bottomed at -$27.0 million in Q3 2024.
• Historically, Change in Acquisitions & Divestments has averaged $13.1 million across 5 years, with a median of $5.4 million in 2025.
• Annual changes were most pronounced in 2023 — Change in Acquisitions & Divestments slumped 100.53% — and 2024, when it surged 46217.65%.
• ImmunityBio's Change in Acquisitions & Divestments stood at $56000.0 in 2022, then soared by 17935.71% to $10.1 million in 2023, then sank by 367.33% to -$27.0 million in 2024, then surged by 320.54% to $59.5 million in 2025, then sank by 33.08% to $39.8 million in 2026.
• Business Quant data shows IBRX's Change in Acquisitions & Divestments at $39.8 million in Q1 2026, $59.5 million in Q4 2025, and $5.4 million in Q1 2025.